<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929563</url>
  </required_header>
  <id_info>
    <org_study_id>2173</org_study_id>
    <nct_id>NCT02929563</nct_id>
  </id_info>
  <brief_title>Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial</brief_title>
  <acronym>PIC-UP</acronym>
  <official_title>Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the feasibility of a large study of stress ulcer prophylaxis in critically&#xD;
      ill children. Children admitted to the Pediatric Intensive Care Unit who are expected to&#xD;
      require mechanical ventilation for more than 48 hours will be randomized to intravenous&#xD;
      pantoprazole 1 mg/kg or matching placebo once daily until they no longer need mechanical&#xD;
      ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite sparse pediatric data on the effectiveness of stress ulcer prophylaxis to prevent&#xD;
      gastrointestinal (GI) bleeding, 60% of critically ill children receive these medications.&#xD;
      This may have unintended consequences - increasing the risk of nosocomial infections - which&#xD;
      may be more serious and common than bleeding these drugs are prescribed to prevent. A large&#xD;
      randomized trial (RCT) is needed to assess the balance of these risks and benefits, to&#xD;
      determine if a strategy of withholding stress ulcer prophylaxis in critically ill children is&#xD;
      not inferior to a strategy of routine stress ulcer prophylaxis. RCTs in pediatric critical&#xD;
      care are exceptionally challenging to complete; thus, a rigorous pilot RCT is crucial. The&#xD;
      pilot may prevent pursuit of a trial that is ultimately not feasible - which is ethically and&#xD;
      financially responsible. It is more likely that this carefully designed pilot trial will&#xD;
      ensure that the larger trial we undertake is successful.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective screening</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>We will consider the trial feasible if &gt;80% of eligible patients are approached for consent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timely enrollment</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>We will consider the trial feasible if &gt;80% of participants receive their first dose of the assigned study drug within 1 day of becoming eligible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant accrual</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>We will consider the trial feasible if the average monthly enrollment is 2 or more participants per centre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol adherence</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>We will consider the trial feasible if &gt;90% of doses are administered according to the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically important bleeding</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>Overt bleeding from the GI tract (can be hematemesis, nasogastric blood, melena, hematochezia) associated with one of the following within 24 hours: a decrease in hemoglobin of &gt;20 g/L, hypotension (a decrease in systolic blood pressure of &gt;10 mmHg or the need for new or increased doses of vasoactive medications), tachycardia (an increase in heart rate of &gt;20 beats per minute) or a red blood cell transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infections</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>Ventilator associated pneumonia and C Difficile associated diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other gastrointestinal bleeding</measure>
    <time_frame>During admission to the Pediatric Intensive Care Unit (to maximum of 30 days)</time_frame>
    <description>Bleeding from the gastrointestinal tract that is not clinically important (using the above criteria).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (for pantoprazole)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <arm_group_label>pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for pantoprazole)</intervention_name>
    <arm_group_label>placebo (for pantoprazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. less than 18 years of age&#xD;
&#xD;
          2. &gt;4 months of age&#xD;
&#xD;
          3. requires respiratory support in the form of invasive mechanical ventilation,&#xD;
             non-invasive mechanical ventilation, or high-flow oxygen&#xD;
&#xD;
          4. the attending physician expects the child to require respiratory support for at least&#xD;
             2 more days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. histamine-2 receptor antagonist (H2RA) or proton pump inhibitor (PPI) use for &gt;1 week&#xD;
             in the past month&#xD;
&#xD;
          2. active GI bleeding Blood in the nasogastric (NG) tube or coffee-ground emesis&#xD;
             suspected by the attending physician to be from the oropharynx is not an exclusion&#xD;
             criterion.&#xD;
&#xD;
          3. documented severe reflux, active H. pylori infection, severe esophagitis, Zollinger&#xD;
             Ellison syndrome, Barrett's esophagus, peptic ulcer bleeding within 8 weeks&#xD;
&#xD;
          4. are receiving methylprednisolone 15 mg/kg/day or more (or equivalent) Equivalent&#xD;
             doses: methylprednisolone, prednisone or prednisolone 15 mg/kg/day; dexamethasone 3&#xD;
             mg/kg/day; hydrocortisone 60 mg/kg/day&#xD;
&#xD;
          5. are receiving mycophenolate (enteral), methotrexate, nelfinavir, atazanavir,&#xD;
             saquinavir, posaconazole&#xD;
&#xD;
          6. chronic ventilation on usual pressure settings and rate&#xD;
&#xD;
          7. nocturnal or intermittent non-invasive ventilation only&#xD;
&#xD;
          8. are eating, nursing, or if chronically fed via feeding tube, receiving usual feeds&#xD;
&#xD;
          9. received more than 1 daily-dose equivalent of acid suppressive medication in the PICU&#xD;
&#xD;
         10. were previously enrolled in this trial&#xD;
&#xD;
         11. are currently enrolled in a potentially confounding trial&#xD;
&#xD;
         12. are known to be pregnant or breastfeeding&#xD;
&#xD;
         13. are known to be allergic to pantoprazole or any other ingredient in the product&#xD;
&#xD;
         14. are not expected to survive this PICU admission because of palliative care or limited&#xD;
             life support&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Duffett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

